secwatch.observer — SEC 8-K summary
======================================

Issuer:     DBV Technologies S.A. (DBVT)
CIK:        0001613780
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0001193125-24-188937
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DBV reports Q2 net loss $33.1M, cash $66.2M, going concern doubt; VITESSE on track
--------------------------------------------------------------------------------

- Q2 net loss of $33.1M (US GAAP), basic EPS -$0.34 vs -$0.26 in Q2 2023.
- Cash and equivalents $66.2M at June 30, 2024, down from $141.4M at Dec 31, 2023; cash runway extended into Q1 2025.
- Substantial doubt about going concern; expects to need additional capital to fund operations.
- VITESSE Phase 3 enrollment in 4-7-year-olds on track to complete screening by end of Q3 2024.
- Submitted labeling proposal to FDA for COMFORT Toddlers (1-3-year-olds) using EPITOPE data to identify responders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613780/000119312524188937/0001193125-24-188937-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613780/000119312524188937/d869824d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-188937

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer